Artificial heart to give new hope to heart failure patients
A revolutionary, implantable mechanical device to be tested at The Alfred is set to provide new hope to patients with debilitating heart failure.
Visitor information – Everything you need to know about visiting our sites.
The Alfred Heart Failure and Transplant service remains committed to ongoing research to improve the quality of lives for patients living with VADs and advancing the management of these patients for the best clinical outcomes.
The Heart Failure and Transplant service at The Alfred cares for approximately twenty five to thirty patients with ventricular assist devices (VADs) per year.
From the first clinical research trial of the Australian designed VentrAssist VAD in 2002 we remain involved in research of the newest ventricular assist devices, most recently the HeartMate III as part of an international multi-centre collaborative research trial.
Particular foci of research currently include ventricular assist device driveline infections, the haemodynamics of VADs with exercise, acute and long-term rehabilitation programmes for best physical outcomes post surgical implantation, quality of life of patients living with VADs and anticoagulation monitoring.
Professor Kaye is the Director of Cardiology and a senior cardiologist in the Heart Failure & Transplant service at The Alfred.
A revolutionary, implantable mechanical device to be tested at The Alfred is set to provide new hope to patients with debilitating heart failure.
Heart patients of the future are set to benefit from a new partnership which will bring together the combined strengths of three leading institutions in cardiovascular research and patient care.
When 43-year-old Melbourne dad Mark Wohlers suffered a cardiac arrest last year, it was the swift emergency response and an Australian-first clinical trial that gave him a second chance at life.